Disease-modifying therapy in multiple sclerosis

Strategies for optimizing management

Elliot Frohman, Ted Phillips, Kristen Kokel, Jerry Van Pelt, Shirley O'Leary, Shelly Gross, Kathleen Hawker, Michael Racke

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

BACKGROUND - The objective for this article is to highlight several challenges faced by patients and providers in the utilization of disease-modifying agent (DMA) therapy in multiple sclerosis (MS) and to offer practical management strategies that can effectively mitigate or even prevent limiting adverse reactions and enhance treatment compliance. REVIEW SUMMARY - Our discussion will be limited to the use of interferon β1a (Avonex, Rebif), interferon β1b (Betaseron), and glatiramer acetate (Copoxane) as these are the primary agents used in the United States for primary disease-modifying therapy in relapsing forms of MS. Some of the recommendations contained herein are derived from evidence-based studies, while others are contingent upon our collective clinical experiences. At the University of Texas Southwestern Medical Center at Dallas and Texas Neurology in Dallas we actively follow approximately 5000 MS patients. The majority of our patients with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) are treated with one of the currently available DMAs. Our experience with these patients, and the challenges they face in continuing long-term treatment, constitutes the basis of our proposed treatment strategies. As part of this effort we formulated an assessment and intervention instrument that can be used in the clinic and by telephone to enhance compliance and minimize adverse events. CONCLUSION - A comprehensive treatment approach to the utilization of disease-modifying therapy in MS can serve to optimize the management of our patients and effectively meet the challenges that arise during the course of treatment.

Original languageEnglish (US)
Pages (from-to)227-236
Number of pages10
JournalNeurologist
Volume8
Issue number4
StatePublished - 2002

Fingerprint

Multiple Sclerosis
Therapeutics
Interferons
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Neurology
Telephone
Compliance

Keywords

  • Flu-like symptoms
  • Glatiramer acetate
  • Interferon beta
  • Skin reactions

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Frohman, E., Phillips, T., Kokel, K., Van Pelt, J., O'Leary, S., Gross, S., ... Racke, M. (2002). Disease-modifying therapy in multiple sclerosis: Strategies for optimizing management. Neurologist, 8(4), 227-236.

Disease-modifying therapy in multiple sclerosis : Strategies for optimizing management. / Frohman, Elliot; Phillips, Ted; Kokel, Kristen; Van Pelt, Jerry; O'Leary, Shirley; Gross, Shelly; Hawker, Kathleen; Racke, Michael.

In: Neurologist, Vol. 8, No. 4, 2002, p. 227-236.

Research output: Contribution to journalArticle

Frohman, E, Phillips, T, Kokel, K, Van Pelt, J, O'Leary, S, Gross, S, Hawker, K & Racke, M 2002, 'Disease-modifying therapy in multiple sclerosis: Strategies for optimizing management', Neurologist, vol. 8, no. 4, pp. 227-236.
Frohman E, Phillips T, Kokel K, Van Pelt J, O'Leary S, Gross S et al. Disease-modifying therapy in multiple sclerosis: Strategies for optimizing management. Neurologist. 2002;8(4):227-236.
Frohman, Elliot ; Phillips, Ted ; Kokel, Kristen ; Van Pelt, Jerry ; O'Leary, Shirley ; Gross, Shelly ; Hawker, Kathleen ; Racke, Michael. / Disease-modifying therapy in multiple sclerosis : Strategies for optimizing management. In: Neurologist. 2002 ; Vol. 8, No. 4. pp. 227-236.
@article{0d10c26453544081bff39de3ade9c36a,
title = "Disease-modifying therapy in multiple sclerosis: Strategies for optimizing management",
abstract = "BACKGROUND - The objective for this article is to highlight several challenges faced by patients and providers in the utilization of disease-modifying agent (DMA) therapy in multiple sclerosis (MS) and to offer practical management strategies that can effectively mitigate or even prevent limiting adverse reactions and enhance treatment compliance. REVIEW SUMMARY - Our discussion will be limited to the use of interferon β1a (Avonex, Rebif), interferon β1b (Betaseron), and glatiramer acetate (Copoxane) as these are the primary agents used in the United States for primary disease-modifying therapy in relapsing forms of MS. Some of the recommendations contained herein are derived from evidence-based studies, while others are contingent upon our collective clinical experiences. At the University of Texas Southwestern Medical Center at Dallas and Texas Neurology in Dallas we actively follow approximately 5000 MS patients. The majority of our patients with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) are treated with one of the currently available DMAs. Our experience with these patients, and the challenges they face in continuing long-term treatment, constitutes the basis of our proposed treatment strategies. As part of this effort we formulated an assessment and intervention instrument that can be used in the clinic and by telephone to enhance compliance and minimize adverse events. CONCLUSION - A comprehensive treatment approach to the utilization of disease-modifying therapy in MS can serve to optimize the management of our patients and effectively meet the challenges that arise during the course of treatment.",
keywords = "Flu-like symptoms, Glatiramer acetate, Interferon beta, Skin reactions",
author = "Elliot Frohman and Ted Phillips and Kristen Kokel and {Van Pelt}, Jerry and Shirley O'Leary and Shelly Gross and Kathleen Hawker and Michael Racke",
year = "2002",
language = "English (US)",
volume = "8",
pages = "227--236",
journal = "Neurologist",
issn = "1074-7931",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Disease-modifying therapy in multiple sclerosis

T2 - Strategies for optimizing management

AU - Frohman, Elliot

AU - Phillips, Ted

AU - Kokel, Kristen

AU - Van Pelt, Jerry

AU - O'Leary, Shirley

AU - Gross, Shelly

AU - Hawker, Kathleen

AU - Racke, Michael

PY - 2002

Y1 - 2002

N2 - BACKGROUND - The objective for this article is to highlight several challenges faced by patients and providers in the utilization of disease-modifying agent (DMA) therapy in multiple sclerosis (MS) and to offer practical management strategies that can effectively mitigate or even prevent limiting adverse reactions and enhance treatment compliance. REVIEW SUMMARY - Our discussion will be limited to the use of interferon β1a (Avonex, Rebif), interferon β1b (Betaseron), and glatiramer acetate (Copoxane) as these are the primary agents used in the United States for primary disease-modifying therapy in relapsing forms of MS. Some of the recommendations contained herein are derived from evidence-based studies, while others are contingent upon our collective clinical experiences. At the University of Texas Southwestern Medical Center at Dallas and Texas Neurology in Dallas we actively follow approximately 5000 MS patients. The majority of our patients with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) are treated with one of the currently available DMAs. Our experience with these patients, and the challenges they face in continuing long-term treatment, constitutes the basis of our proposed treatment strategies. As part of this effort we formulated an assessment and intervention instrument that can be used in the clinic and by telephone to enhance compliance and minimize adverse events. CONCLUSION - A comprehensive treatment approach to the utilization of disease-modifying therapy in MS can serve to optimize the management of our patients and effectively meet the challenges that arise during the course of treatment.

AB - BACKGROUND - The objective for this article is to highlight several challenges faced by patients and providers in the utilization of disease-modifying agent (DMA) therapy in multiple sclerosis (MS) and to offer practical management strategies that can effectively mitigate or even prevent limiting adverse reactions and enhance treatment compliance. REVIEW SUMMARY - Our discussion will be limited to the use of interferon β1a (Avonex, Rebif), interferon β1b (Betaseron), and glatiramer acetate (Copoxane) as these are the primary agents used in the United States for primary disease-modifying therapy in relapsing forms of MS. Some of the recommendations contained herein are derived from evidence-based studies, while others are contingent upon our collective clinical experiences. At the University of Texas Southwestern Medical Center at Dallas and Texas Neurology in Dallas we actively follow approximately 5000 MS patients. The majority of our patients with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) are treated with one of the currently available DMAs. Our experience with these patients, and the challenges they face in continuing long-term treatment, constitutes the basis of our proposed treatment strategies. As part of this effort we formulated an assessment and intervention instrument that can be used in the clinic and by telephone to enhance compliance and minimize adverse events. CONCLUSION - A comprehensive treatment approach to the utilization of disease-modifying therapy in MS can serve to optimize the management of our patients and effectively meet the challenges that arise during the course of treatment.

KW - Flu-like symptoms

KW - Glatiramer acetate

KW - Interferon beta

KW - Skin reactions

UR - http://www.scopus.com/inward/record.url?scp=0036327024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036327024&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 227

EP - 236

JO - Neurologist

JF - Neurologist

SN - 1074-7931

IS - 4

ER -